GLP-1 Side Effects: What Australians Need to Know Before Starting a Weight Management Program

GLP-1 receptor agonists have become an established part of medically supervised weight management in Australia. As awareness of this class of prescription medicine has grown, so too has the number of Australians asking good questions about them — including what the side effect profile actually looks like, and what it means for them individually.

That's a sensible place to start. All prescription medicines carry a risk-benefit profile, and GLP-1 receptor agonists are no exception. Understanding the side effects — common, less common, and rare — puts patients in a better position to have an informed conversation with their doctor before making any decisions.

This article outlines the key side effects associated with GLP-1 receptor agonists as a class, explains what the adjustment period typically looks like, and describes why GP supervision is central to managing these effects safely. It is educational information, not a substitute for a clinical assessment.

---

What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists are a class of prescription medicine that mimic glucagon-like peptide-1, a hormone naturally produced in the gut after eating. At a pharmacological level, they slow gastric emptying, influence appetite signalling in the brain, and improve insulin sensitivity.

In Australia, these medicines are prescription-only and require assessment by a registered GP before any prescription is issued. They are used in the management of both type 2 diabetes and, under appropriate clinical circumstances, weight management — always as part of a broader medically supervised program. The HPH medical weight loss program includes GP assessment, clinical oversight, and structured protocols for exactly this reason.

---

The Most Common GLP-1 Side Effects

The majority of side effects associated with this class of medicine occur in the gastrointestinal system, particularly in the early weeks of treatment. The most commonly reported include:

Nausea

Nausea is the most frequently reported side effect across this class and is particularly common during the early dose-titration period. For most patients, it is mild to moderate and tends to reduce as the body adjusts. It is most often experienced in the hours following injection.

Vomiting

Vomiting occurs less frequently than nausea but is reported by a meaningful proportion of patients, again primarily in the early weeks. Severe or persistent vomiting warrants contact with your GP, as it can lead to dehydration if unmanaged.

Diarrhoea and Constipation

Both ends of the gastrointestinal spectrum are reported. Some patients experience loose stools or diarrhoea, while others experience constipation. These effects are generally self-limiting but should be discussed with your supervising GP if they are prolonged or disruptive.

Stomach Discomfort and Bloating

Abdominal discomfort, bloating, and a sense of fullness are commonly reported, particularly after eating. Adjusting meal size and composition — specifically, eating smaller portions and avoiding fatty or spicy foods — is standard advice given during the adjustment period.

Reduced Appetite

Reduced appetite is both a pharmacological effect of this class and commonly reported by patients — your GP will contextualise this as part of your assessment.

Fatigue

Some patients report fatigue in the early weeks of treatment. This is generally transient and often coincides with the peak of gastrointestinal symptoms.

---

Less Common but Notable Side Effects

Beyond the gastrointestinal effects, a smaller proportion of patients report:

• Headaches, particularly in the first few weeks
• Dizziness, which may relate to reduced caloric intake or postural changes
• Injection site reactions — mild redness, swelling, or tenderness at the site of subcutaneous injection; these are generally minor and resolve quickly
• Altered taste perception, reported by some patients, most commonly a change in palatability of certain foods
• Sleep disturbances in the early adjustment period, though this is less well-documented

These effects are worth knowing about but are not experienced by the majority of patients. Your GP will ask about any new or unusual symptoms at monitoring appointments.

---

Rare but Serious Side Effects

The following side effects are uncommon but are clinically significant. They form part of the reason that prescribing and monitoring within a supervised program — rather than an unsupervised script — is considered best practice.

Pancreatitis

Acute pancreatitis is a rare but documented risk associated with this class of medicine. The key warning signs are persistent, severe upper abdominal pain that may radiate through to the back, particularly if accompanied by nausea and vomiting. If these symptoms occur, patients are advised to stop the medicine and seek urgent medical review. A prior history of pancreatitis is a contraindication to starting this class of medicine.

Gallbladder Issues

Cholelithiasis (gallstones) and related gallbladder conditions have been reported with longer-term use of GLP-1 receptor agonists. The mechanism relates to changes in gallbladder motility. This is not a reason to avoid the medicine, but it is part of the clinical picture a GP monitors over time.

Thyroid Considerations

Certain thyroid conditions — specifically a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) — represent contraindications to this class of medicine. This is assessed during the initial clinical review.

Severe Dehydration

Persistent vomiting or diarrhoea, if unmanaged, can result in dehydration. Patients who are unable to maintain adequate fluid intake should contact their GP promptly.

These serious side effects are uncommon. Their presence in the risk profile is precisely why this class of medicine is prescribed within a supervised clinical framework and not available over the counter.

---

Why the First 4–8 Weeks Are the Adjustment Period

Dose titration — beginning at a low dose and increasing incrementally — is the standard clinical approach with GLP-1 receptor agonists. This is not arbitrary caution; it is a pharmacological strategy to minimise gastrointestinal side effects by giving the body time to adapt.

The majority of side effects in this class are most pronounced in the early weeks, when the dose is at its lowest. As titration progresses, many patients find that symptoms reduce even as the therapeutic dose increases.

Practical measures commonly recommended during this period include:

• Eating smaller, more frequent meals rather than large portions
• Avoiding high-fat, spicy, or heavily processed foods
• Staying well-hydrated
• Taking the injection at a consistent time, sometimes in the evening to sleep through early nausea
• Keeping a brief symptom log to discuss with your GP

The GP-prescribed protocols used within a structured program include clear guidance on managing side effects at each stage of titration.

---

Who Should Not Start a GLP-1 Program

Not every patient is a candidate for this class of medicine. Conditions that typically represent contraindications or require careful clinical consideration include:

• Active pancreatitis, or a documented history of pancreatitis
• Personal or family history of medullary thyroid carcinoma or MEN2
• Pregnancy or breastfeeding — this class of medicine is not appropriate during either
• Severe gastrointestinal disorders, including gastroparesis
• Significant renal or hepatic impairment — requires assessment of dose appropriateness

This is not an exhaustive list of contraindications — your GP will conduct a full assessment.

---

How GP Supervision Manages Side Effects

The clinical value of a supervised program is most visible in how side effects are handled. In a well-structured program, the sequence looks like this:

1. Initial consult: Full clinical history, relevant blood tests, exclusion criteria check, and a discussion of all relevant options before any prescription is issued.
2. Dose titration schedule: A structured escalation plan — not a fixed starting dose with no review — designed to minimise early side effects.
3. Monitoring appointments: Regular check-ins (not a set-and-forget prescription) to assess response, tolerability, and clinical progress.
4. Dose adjustment as needed: If side effects are significant, the dose can be held, reduced, or the program paused. This is normal clinical practice, not a failure.
5. Access to your GP throughout: Any new or concerning symptoms between scheduled appointments can be raised directly with the supervising doctor.

This is the substantive difference between a GP-supervised program and simply obtaining a script through the path of least resistance.

---

Questions to Ask Your GP About Side Effects

Arriving at your first consult with clear questions makes the appointment more useful. Consider asking:

1. What side effects are most likely given my individual health history?
2. How will we handle it if my nausea is severe — is there a pause protocol?
3. What symptoms should prompt me to contact you between appointments?
4. How long does the adjustment period typically last?
5. Are there any interactions with my current medications I should know about?
6. What is the plan if I need to stop — is there a tapering protocol?

A GP who takes time to answer these questions is a better clinical partner than one who does not.

---

Conclusion

Side effects are a real and expected part of starting any prescription medicine, and GLP-1 receptor agonists are no different. For most patients, the gastrointestinal effects are the most significant — and most are manageable with proper titration, dietary adjustments, and clinical support.

The serious side effects associated with this class are uncommon but not negligible, which is precisely why this class of medicine is prescription-only and why a supervised program offers a meaningfully safer environment than an unsupervised script. GPs help patients weigh clinical considerations on both sides — the risks of the medicine, and the clinical significance of the condition it is being used to treat. That balance is a conversation for you and your doctor, not a conclusion drawn from an article.

If you are considering a GLP-1 weight management program, the right first step is a clinical assessment with a qualified GP. Speak to an HPH GP to discuss whether this approach is appropriate for your individual circumstances.